Comorbidities are frequent in chronic obstructive pulmonary disease (COPD) and
significantly impact on patients' quality of life, exacerbation frequency, and survival. There is …

Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a
network meta‐analysis - Kew, KM - 2014 | Cochrane Library Skip to Content Cookies Our site …

Introduction We defined “ultracentral” lung tumors as centrally located non–small cell lung
cancers with planning target volumes overlapping the trachea or main bronchi. Increased …

Background Findings from studies done over the past 20 years suggest that mortality from
chronic obstructive pulmonary disease (COPD) is decreasing worldwide, but little …

COPD is one of the major public health problems in people aged 40 years or above. It is
currently the 4th leading cause of death in the world and projected to be the 3rd leading …

Background Little data exist on causes of death in cystic fibrosis (CF) patients in the era of
lung transplantation. Methods Deaths in CF patients in France (2007–2010) were identified …

Background Anxiety and depression are prevalent among individuals with chronic
obstructive pulmonary disease (COPD), but the impact of these comorbidities on long-term …

Significant cardiac morbidity and mortality exists in patients with COPD. Shared risk factors
include age, smoking history and exposure to air pollution and passive smoke. Although the …

Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …

Background Assessment of events by adjudication committees (ACs) is recommended in
multicentre randomised controlled trials (RCTs). However, its usefulness has been …